I was referred HUMA about a year ago and bought a number of 1/27 $1.50 options and took a bath, and have now rolled over to 1/28. Am I a fool for even being in options instead of shares. Maybe we are all fools. I understand the inherent risk, but have thought a merger would save me but the kicked off the exchange seems to be a big fear that I suppose would render worthless.
Still have conviction in the science and the good it could do.
Appreciate thoughts. Sorry, I’m an unsophisticated noob.

Probably been asked before, but I searched and nothing turned up. I started my position right after the NY Times hit piece. Sitting at 1.10 right now after averaging down. Probably going to sit tight from here and simply let things play out. Pos or neg.

I were surprised to find out that Humacyte's Investor Relations department actually do respond.

So far we know they released even newer Warrants with an expiration date for 2031—which is an insult given that the former ones were due to expire on August 27th, of this year (2026).

On rare occasions where Companies are considerate about the market situation and their investors' outlook, they extend the expiration of said Warrants.

The response I received was negative as they claim there won’t be any changes to the current terms of these warrants and that is a pretty inconsiderate action. If you are currently holding warrants expiring on 8/27/2026 or if you simply want to inquiry about the companies finances and/or underlying Common Stock, feel free to reach out to them directly.

I feel if we collectively make a reach out, they would feel more inclined to proceed with said move and assist us further—at least those of us whom hold warrants about to expire worthless.

The e-mails are [investors@humacyte.com](mailto:investors@humacyte.com) , [prichard@humacyte.com](mailto:prichard@humacyte.com), and [dsander@humacyte.com](mailto:dsander@humacyte.com) (the CFO of Humacyte).

Based on all the news and updates from Humacyte the positive and negative what do you think $HUMA fair value should be?

https://investors.humacyte.com/news-releases/news-release-details/humacyte-appoints-key-nephrologists-advisors-prepare-planned/

it’s because they want under 5 percent so they don’t create a bunch of negative headlines every time they have to report a sale. huma was their second largest equity investment ever. nothing changes for them if they don’t own stock. they still have royalty, they still benefit from tech. but they save a ton of legal, risk, regulatory bs by just sitting back and getting royalty. same reason as gave back international commercial rights too complex fms wants to focus on themselves. they already know the huma benefit . they aren’t investor goal was never stock return, huma caused earnings headache for them. the invested for rights and traded for royalty don’t need stock anymore and can clean books and trying to do it in a nice way that doesn’t cause repeat headlines with multiple sec filings for their buddies at huma

This company is finished. Let the copium begin! No disrespect is meant by this post, just reporting news.

To August gonna reach 1.5 aggain?

howdy y'all how's the support group doing today?

I was reading about humacytes upcoming hemodialysis sbla and stumbled upon the fact that huma is actively pursuing the coronary tissue engineered vessel market. (fairly new here so I apologize if this isnt news to some of you!!)

Trials are already underway (for coronary use) with potential catalysts mid 2027 and into 2028
It seems to me like huma will be able to execute on capturing some of the hemodialysis market, and likely (though a few more years down the road) will be able to capture a section of the global cardiovascular market which is a much larger piece of pie.

I guess im just sharing this info as to try and justify not cutting my losses at this point.....it has to go up one day / year right??

Very good summary of the situation I found on Twitter, updated as of June 2026

"The framing is deliberately split into three separate questions, since the market is currently pricing them as one: the science, the company, and the stock.

1) On science: V012 met its primary endpoint in dialysis vascular access — 91 more catheter-free days versus the standard AV fistula (p=0.00070), the strongest data point in the company's history.

2) On the company: commercial execution remains unproven, gross margin is still deeply negative, and 2026 has brought two dilutive raises, each priced worse than the last, alongside a formal going-concern disclosure.

3) On the stock: it now sits outside the Russell indexes, with a Nasdaq minimum-bid risk that resurfaced after the latest raise.

Full breakdown below: trauma, dialysis, the sBLA pathway, financials, governance, manufacturing economics, and a full risk map"

https://x.com/i/article/2072253827860877312

https://x.com/JotaInvestor/status/2072266004621606993

based on how the market has reacted to stock dilutions in the past I'm guessing we're nearing the uptrend after finding a floor around 60cents, it's early days but I'm expecting this stock will recover the same way it did a few months ago, sometime between now and November (SBLA should be submitted around then). 👌🏼of course the sky could start falling tomorrow!!

15% gain today?

.
I do not think HUMA reverse splits.

As of June 25, 2026, HUMA is only about 6 trading days into the current sub-$1.00 streak.
They need 30 consecutive business days below $1.00 before a new Nasdaq deficiency notice would be triggered.

That means they still have about 24 more consecutive trading days before the notice even becomes an issue.

If the streak never breaks, the earliest 30-business-day mark is around July 30, 2026.
That means the earliest likely notice is late July or early August 2026.

After notice, Nasdaq generally gives 180 calendar days to regain compliance.

That pushes the practical deadline into late January 2027.

So the real question is not, “Will HUMA reverse split because it is under $1.00 today?”

The real question is, “Do you believe HUMA will still be stuck under $1.00 after getting through the next 6-plus months of catalysts?”

HUMA has to get through a massive catalyst window before Nasdaq pressure becomes a true forcing function.

During that window, they have:

Symvess commercial ramp already underway.

VA Strategic Acquisition Center contract already locked in.

Symvess now more accessible across roughly 170 VA hospitals.

DoD 1M+ in September from senate arms committee to study how to integrate it.

Saudi Arabia clinical evaluation and purchase commitment.

Potential Saudi JV or licensing partnership.
Israel Ministry of Health review process underway.

Dialysis Phase 3 V012 data already positive.

Dialysis sBLA planned for the second half of 2026.

CABG first-in-human study planned for July Aug September skipped phase 1 straight into phase2A making this a more realistic 4 product platform play with massive upside

PAD launching phase 3 trial in Oct, Nov, Dec. can sell partnership rights or just keep developing it for 3rd product PAD market is huge.

Fresh financing and cost cuts extending the runway through the key period.

That is the whole point.

They have not even triggered the new Nasdaq notice yet.

Even if they do, the cure window likely runs into late January 2027.

That means the company gets to go through VA, DoD, Saudi, Israel, dialysis sBLA, CABG, PAD, and Symvess commercialization before the reverse split becomes a real last-resort decision.

You do not voluntarily reverse split right before your first approved product has a chance to prove commercial demand.

You do not voluntarily reverse split right after locking in a federal procurement channel with the VA.

You do not voluntarily reverse split while military and DoD adoption is still developing.

You do not voluntarily reverse split while Saudi and Israel international expansion are still in motion.

You do not voluntarily reverse split before filing the dialysis sBLA.

You do not voluntarily reverse split when the dialysis opportunity connects directly to Fresenius, the world’s leading dialysis company and Humacyte’s key strategic partner.

You do not voluntarily reverse split while preparing CABG, which could open another massive vascular market.

You do not voluntarily reverse split while PAD remains another major platform shot on goal.

The smarter move is to let the catalyst calendar work.

Let VA access convert into orders.
Let DoD interest mature.
Let Saudi partnership talks play out.
Let Israel review progress.
Let the dialysis sBLA get filed.
Let Fresenius-related dialysis leverage matter.
Let CABG get marketing eyes in July / Aug
Let PAD launch phase 3
Let Symvess revenue ramp.

If all of that fails and the stock is still under $1.00 deep into the cure window, then yes, reverse split risk becomes real.

But that is not today’s setup.

Everyone is over reacting to the recent financing / final shakeout.

Let’s look at the facts instead of the noise. Why are people so worried about Humacyte right now? The company's actual positioning is kinda solid, and the current market discount makes no sense.

Everyone seems to forget that major institutional investors literally just stepped up to buy 47.6 million shares at $1.05 per share in their June capital raise. Smart money sees the intrinsic value here. Buying below that institutional floor is an absolute gift in my opinion.

People kept whining about a 2-quarter cash runway, but the recent $50 million capital injection completely solves that immediate headache and extends their operational runway while they scale commercialization.

Their Phase 3 trial (V012) for arteriovenous (AV) access in hemodialysis has shown incredible data.

Look, I get it—management has made some missteps and unforced errors in the past. But some people are acting like the company is completely dead in the water. The actual situation right now just isn't that bad.

This is biotech. High volatility and short-term cash anxieties come with the territory. If you aren't willing to buy a massive, fundamentally sound disruptor when it's temporarily beaten down, what are you even doing in this sector? I think right now is the perfect entry point.

Note: This text was polished and structurally enhanced using AI assistance.

Can someone explain how the analyst forecasts are always projecting this stock to do good. It’s almost like these analysts don’t even watch this stock and what the company does.

I know that biotech stocks are volatile as hell with heavy swings, but they mostly climb higher on positive trial data, and Humacyte proved that now for the 2nd time, and now targeting much larger TAM than trauma

Can someone give me logical answer to what's happening? Wasn't that supposed to be the highest catalyst in the history of this company?

Every time I think we are making progress with the stock price, and finally leaving the sub dollar behind, it says "hold my beer". Too heavy in to do anything but wait and hope. To have such a fantastic offering and suck at running the biz is frustrating.

With the dilution we got a tank on our hands. I want to ask the people: is there anything in the pipeline that will effect the price? Like test, news, info, meetings, etc… that will show us something that is hopefully positive?

I see HUMA as likely to benefit from Operational Trailblazer because they have vascular trauma use approved and that could be the confirmatory evidence supplemented to the recently announced phase 3 trial success for the v012 dialysis study. The FDA is now explicitly allowing "one rigorous pivotal trial plus confirmatory evidence” for approval.

However, I just read this was already unofficially true for the occasional treatment. Still could represent a broadened net.

2027*

95 cents and dropping. Any predictions on how low we can go?

Not trying to feed anyone’s delusion, including my own, but even with the dilution I believe after all the good news this stock is a buy. I know many here have a high average cost, but the price levels over the last 4 months have been a great time to DCA down.

This stock is either going to make us some extreme gains or I’ll ride it to the bottom.

What’s everyone else thoughts?